Loading...
•
Mar 31, 2023
AcelRx Q1 2023 Earnings Report
AcelRx reported first quarter 2023 financial results and provided a corporate update.
Key Takeaways
AcelRx Pharmaceuticals reported a net loss attributable to common shareholders of $8.2 million, or $0.75 per basic and diluted share, for the first quarter of 2023. The company closed the divestment of DSUVIA to Alora Pharmaceuticals and submitted a request for an Emergency Use Authorization for Niyad.
Submitted a request for an EUA for Niyad on April 27, 2023.
Closed the divestment of DSUVIA to Alora Pharmaceuticals on April 3, 2023.
Cash and cash equivalents balance was $13.4 million as of March 31, 2023.
Net loss attributable to common shareholders for the first quarter of 2023 was $8.2 million, or $0.75 per basic and diluted share.
Forward Guidance
AcelRx is focused on initiating the FDA-informed single registrational study for Niyad in the second half of this year and has agreed upon terms for the supply of the active pharmaceutical ingredient.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...